No company description available.
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The Associate Director, Integrated Research Management provides leadership across Research disciplines to strengthen operational execution, organizational clarity, and cross-functional alignment within the Discovery organization.
Revolution Medicines